



Press Release

mtm laboratories and Dako restructure license agreement regarding p16INK4a CINtec®

Heidelberg, Germany; May 2, 2006. mtm laboratories and Dako have restructured their 2001 licensing agreement under which mtm licensed the CINtec® In-vitro Diagnostic technology to Dako for development and commercialisation. The CINtec® In-vitro Diagnostic (IVD) products are based on mtm's technology for the detection of p16INK4a over-expression in biopsies (CINtec® p16INK4a Histology) and cervical cytology specimens (CINtec® p16INK4a Cytology).

Effective January 1 2007, all sales and marketing responsibilities for CINtec® products will transfer to mtm. Up until Dec 31, Dako including its subsidiaries and distributors will continue sales and marketing activities of the currently available CINtec® p16INK4a Histology and CINtec® p16INK4a Cytology products manufactured and labelled by Dako.

mtm laboratories has been very pleased with the results Dako has achieved developing the assay platforms and for initial product adoption in key markets. The timing for this restructuring is based on the expanded capabilities of mtm laboratories, which is now developing IVD products in its ISO 9001 and ISO 13485 certified environment for technical development, clinical development and manufacturing.

Peter Pack, CEO of mtm laboratories, commented: "Over the past few years, mtm laboratories has been establishing and extending its certified development and manufacturing capabilities for in-vitro cancer Diagnostics. By taking over the responsibility for development and commercialization of the CINtec® products, mtm laboratories will reach the next level of maturation to a fully integrated diagnostic company."

mtm laboratories AG is a privately held company based in Heidelberg, Germany with a wholly owned subsidiary in Westborough (MA), USA. The ISO 9001 and ISO 13485 certified company develops In Vitro Diagnostic test systems for the early detection and diagnosis of cancer with a focus on cervical cancer screening, the largest screening market in oncology. Based on mtm's proprietary p16INK4a biomarker, the Company is in the process of developing proprietary cell-based CINtec® assays as well as non cell-based IVD products.